Navigation Links
NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session
Date:3/28/2008

NEW YORK (March 27, 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American College of Cardiology's 57th Annual Scientific Session in Chicago, March 29 to April 1. Among the most significant presentations are the following:

Drug-Eluting Stents Versus Bare-Metal Stents for Transplant Allograft Vasculopathy

Dr. Jeffrey Moses Director of the Center for Interventional Vascular Therapy and director of the Cardiac Catheterization Lab at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons

Heart transplant patients are more vulnerable to accelerated arteriosclerosis in their transplanted heart than the general population. In one of the largest studies of its kind, NewYork-Presbyterian/Columbia researchers found that drug-eluting stents were able to better keep arteries open and prevent narrowing than bare-metal stents. However, mortality rates for interventions were equal.


The Impact of Mandatory Angiographic Follow-up on the One-Year Clinical and Angiographic Results From Endeavor IV: A Randomized Comparison of the Endeavor Drug (ABT-578) Eluting Stent System vs. Taxus in De Novo Native Coronary Lesions

Dr. Martin B. Leon Associate director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is founder and chairman emeritus of the Cardiovascular Research Foundation in New York City.

This presentation will look at follow-up using angiograms and clinical outcomes on patients in the Endeavor IV study, which compares the Endeavor drug-eluting stent with the Taxus drug-eluting stent. The results indicate that clinical follow-up may be more meaningful in determining the true patient value of drug-eluting stents in preventing restenosis, the closing or narrowing of the previously-opened artery.


Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Baseline Renal Function on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Advanced Age on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Is Diabetes a Risk Factor for Restenosis and Adverse Clinical Outcomes After Paclitaxel-Eluting Stent Implantation: Pooled Analysis of the TAXUS IV and TAXUS V Trials

Dr. Gregg W. Stone Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is also chairman of the Cardiovascular Research Foundation in New York City.

Dr. Stone will present new findings from the HORIZONS AMI trial, which is evaluating the drug bivalirudin for heart attack patients undergoing angioplasty. Last year, investigators reported that the therapy reduces risk of death compared with the standard treatment. New findings look at several subsets, including older patients and patients with diabetes, finding bivalirudin also effective for these groups.

In addition, Dr. Stone will present findings from the TAXUS trials looking at the risk of restenosis and other negative outcomes in patients with diabetes with the Taxus drug-eluting stent.


'/>"/>

Contact: Bryan Dotson
brd9005@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. CVS Caremark Presents at NCOA-ASA Conference on Companys Commitment to Recruiting and Retaining Mature Workers
2. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
3. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
4. Accurays CFO to Present at B. Riley & Company Ninth Annual Investor Conference
5. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. UC Irvine researchers present latest findings at emergency medicine forum
8. BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference
9. RNR Public Relations Presents Perfect April Fools Day Feature Opportunity
10. Health Fitness to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
11. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... With the ... through rehabilitation of an injury, patients must find the one that works for them. ... pain, he created a machine that worked and decided to share it with others. ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... , December 2, 2016 On ... trading session in red, while the Dow Jones Industrial Average ... the close of US markets, which prompted Stock-callers this morning ... NuVasive Inc. (NASDAQ: NUVA ), Smith & Nephew ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
(Date:12/2/2016)... , Dec 1, 2016 Research and ... "Drug Delivery in Cancer - Technologies, Markets and Companies" to ... , , ... in management of cancer The market value of drug ... market estimates from 2015-2025 are given according to organs involved and ...
Breaking Medicine Technology: